UPDATE: MKM Partners Reiterates On Auxilium Pharmaceuticals, Inc. As Endo Bid Is Likely Too Low

Loading...
Loading...
In a report published Wednesday, MKM Partners analyst Jon LeCroy reiterated a Buy rating on
Auxilium Pharmaceuticals, Inc.AUXL
, and raised the price target from $26.00 to $32.00. In the report, MKM Partners noted, “Endo International plc (ENDP, $65.17, not covered) announced its proposal to acquire Auxilium for $28.10 per share (half cash, half stock). The deal is valued at $2.2 billion valuation based on Endo's current stock price and Auxilium's debt ($1.4bn excluding debt), a 31% premium to Auxilium's closing price. We assume that Auxilium is willing to sell itself but that Endo will need to pay more than $30.75, which is where the stock traded in February. We think that a $32 bid (50% premium to the September 16 closing price) could be acceptable, but even that may be too low. We note that the stock traded over $35 per share at one point in 2010, so it is possible that Auxilium would want in excess of that amount.” Auxilium Pharmaceuticals closed on Tuesday at $21.52.
Posted In: Analyst ColorPrice TargetAnalyst RatingsJon LeCroyMKM Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...